SecBot SecBot
8-K ·Filed Jul 24, 2026

PROF

Profound Medical Corp.
BULLISH
Impact 6/10
Horizondays Processed3mo ago SEC0001171843-26-004863
Actionable Insight ▲ Bullish

The incremental clinical advantage from CAPTAIN (penile length preservation, plus prior erectile/continence results) supports broader TULSA adoption and may drive procedure volume growth. The stock could trade up near-term as analysts update models. Key catalyst to watch: 1-year primary safety endpoint and 3-year primary efficacy endpoint of CAPTAIN.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.26
T+0 close · Jul 24, 2026 · via day close
Latest settled
−19.28%
T+60 · $5.86
Vs SPY
−22.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 24 $7.26entry
  2. T+1 · 4mo ago +0.96%α +0.94% · $7.33
  3. T+5 · 4mo ago −0.14%α −0.51% · $7.25
  4. T+20 · 3mo ago −6.47%α −10.10% · $6.79
  5. T+60 · 29d ago −19.28%α −22.57% · $5.86
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Profound Medical announced new CAPTAIN trial data showing statistically significant superior penile length preservation with the TULSA Procedure vs robotic radical prostatectomy (no median change vs 0.65 cm reduction at 1 month, p<0.001). This adds to previously reported safety endpoint advantages in erectile function and urinary continence, strengthening the clinical value proposition for TULSA.

Key Facts

  • CAPTAIN trial: no median change in penile length at 1 month after whole-gland TULSA vs 0.65 cm median reduction after robotic RP
  • Between-arm difference statistically significant (0.42 cm, p<0.001)
  • Data presented at Society of Robotic Surgery Annual Meeting, July 24, 2026
  • Previously announced CAPTAIN primary safety endpoint showed TULSA superiority in preserving erectile function and urinary continence at 6 months

Financial Impact

Positive clinical data strengthens TULSA's competitive position vs robotic prostatectomy but no financial figures disclosed in this filing

penile length preservationquality of life outcomes

Risk Factors

  • CAPTAIN primary efficacy endpoint (3-year treatment-free survival) remains unread
  • Market adoption and reimbursement decisions may lag clinical data
  • Competitive response from robotic surgery platforms

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (PROF), Batch item 10001171843-26-004863
Exhibit: exh_991.htm0001171843-26-004863
Document: 0001171843-26-004863-index-headers.html0001171843-26-004863
Document: 0001171843-26-004863-index.html0001171843-26-004863
Document: 0001171843-26-004863.txt0001171843-26-004863
8-K Filing (PROF), Batch item 60001171843-26-004863
Exhibit: exh_991.htm0001171843-26-004863
Document: 0001171843-26-004863-index-headers.html0001171843-26-004863
Document: 0001171843-26-004863-index.html0001171843-26-004863
Document: 0001171843-26-004863.txt0001171843-26-004863

US Market Status

Market Closed · Opens Wed (9h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 24, 2026